Inhibition of voltage-dependent sodium channels by Ro 31-8220, a ‘specific’ protein kinase C inhibitor11Presented in part at the 28th Annual Meeting of the Society for Neuroscience (November 7–12, 1998, Los Angeles, CA, USA).  by Lingameneni, Ratnakumari et al.
Inhibition of voltage-dependent sodium channels by Ro 31-8220,
a ‘speci¢c’ protein kinase C inhibitor1
Ratnakumari Lingamenenia, Tanya N. Vysotskayaa, Daniel S. Ducha;b,
Hugh C. Hemmings Jr.a;c;*
aDepartment of Anesthesiology, Weill Medical College of Cornell University, Box 50, LC-203A, 525 East 68th Street, New York, NY 10021, USA
bDepartment of Physiology and Biophysics, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
cDepartment of Pharmacology, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
Received 20 March 2000
Edited by Maurice Montal
Abstract We find that several protein kinase C (PKC)
inhibitors, previously considered to be specific, directly inhibit
voltage-dependent Na+ channels at their useful concentrations.
Bisindolylmaleimide I (GF 1092037), IX (Ro 31-8220) and V (an
inactive analogue), but not H7 (a non-selective isoquinolinesul-
fonamide protein kinase inhibitor), inhibited Na+ channels
assessed by several independent criteria: Na+ channel-dependent
glutamate release and [3H]batrachotoxinin-A 20-K-benzoate
binding in rat cortical synaptosomes, veratridine-stimulated
22Na+ influx in CHO cells expressing rat CNaIIa Na+ channels
and Na+ currents measured in isolated rat dorsal root ganglion
neurons by whole cell patch-clamp recording. These findings limit
the usefulness of the bisindolylmaleimide class PKC inhibitors in
excitable cells.
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1. Introduction
Speci¢c inhibitors of protein kinases are useful probes for
analyzing signal transduction pathways, but their usefulness
in intact cells can be limited by non-speci¢c actions on other
targets [1]. The bisindolylmaleimide derivatives of staurospo-
rine are widely used as speci¢c inhibitors of conventional pro-
tein kinase C (PKC) isoforms. The speci¢city of inhibitors
such as these, which act as competitive inhibitors of ATP
binding to the nucleotide binding site of PKC [2], is limited
by the conserved protein kinase catalytic domain of most
protein-serine/threonine kinases [3]. This limitation is evident
in recent reports identifying inhibition by bisindolylmale-
imides of other protein kinases, including glycogen synthase
kinase-3 [4], mitogen-activated protein kinase-activated pro-
tein kinase-1L (Rsk-2) and p70 S6 kinase [5], with potencies
greater than or comparable to inhibition of PKC (IC50 values
in the nM range). E¡ects of bisindolylmaleimides on targets
other than protein kinases have also been identi¢ed recently,
including inhibition of 5-hydroxytryptamine3 receptors with a
potency comparable to inhibition of PKC [6], and of chro-
ma⁄n cell nicotinic receptors [7] and human muscarinic re-
ceptors [8] at higher concentrations. Here we report that bis-
indolylmaleimides I (GF 109203X), IX (Ro 31-8220) and V
(inactive against PKC), but not H7 (a non-selective isoquino-
linesulfonamide protein kinase inhibitor), inhibit Na chan-
nels at low micromolar concentrations in rat cortical synap-
tosomes and dorsal root ganglion (DRG) neurons by several
criteria. These ‘non-speci¢c’ actions place considerable restric-
tions on the use of these compounds as PKC inhibitors in
intact cells, particularly in excitable cells.
2. Materials and methods
Experiments were done in accordance with the National Institutes
of Health guidelines for the care and use of laboratory animals as
approved by the Weill Medical College of Cornell University Institu-
tional Animal Care and Use Committee.
2.1. Materials
Bisindolylmaleimides I (GF 109203X), IX (Ro 31-8220) and V were
obtained from Calbiochem (La Jolla, CA, USA); NADP, L-gluta-
mate dehydrogenase (Proteus sp.), bovine serum albumin (BSA; es-
sentially fatty acid free), 4-aminopyridine (4AP), veratridine, tetrodo-
toxin (TTX), scorpion toxin, dimethyl sulfoxide (DMSO), collagenase
(type IV), trypsin (type XII), pronase E (type XIV) and H7 were from
Sigma (St. Louis, MO, USA); Percoll was from Pharmacia (Uppsala,
Sweden); Hanks balanced salt solution, fetal bovine serum, D-MEM/
F-12, penicillin and streptomycin were from Gibco BRL (Gaithers-
burg, MD, USA) and [3H]batrachotoxinin-A 20-K-benzoate
([3H]BTX-B; 34 Ci/mmol) and 22NaCl (1 mCi/ml) were from Du-
Pont-New England Nuclear (Boston, MA, USA). All other chemicals
were of analytical grade.
2.2. Isolation of synaptosomes
Synaptosomes were prepared from the cerebral cortex of adult
Sprague^Dawley rats by the method of Dunkley et al. [9] with minor
modi¢cations [10]. Puri¢ed synaptosomes were suspended in HEPES
(N-[2-hydroxyethyl]piperazine-NP-[2-ethanesulfonic acid]) bu¡ered
medium (HBM; 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.2 mM
Na2HPO4, 5 mM NaHCO3, 10 mM D-glucose and 20 mM HEPES,
pH 7.4 with NaOH), pelleted by centrifugation at 8000Ug for 10 min
and stored on ice for up to 5 h until use.
2.3. Measurement of glutamate release
The release of endogenous glutamate was measured by an enzyme-
linked £uorescence method [11]. Synaptosomal pellets (0.5 mg pro-
tein) were resuspended in 1.5 ml HBM plus 16 WM BSA, 1 mM
NADP, 100 U L-glutamate dehydrogenase, and 1.3 mM CaCl2.
Stirred samples were equilibrated at 37‡C for 4 min in a spectro£uor-
ometer cuvette and data acquisition was started (excitation wave-
length = 340 nm; emission wavelength = 460 nm). After recording
basal £uorescence change (vF) for 60 s, inhibitors (1.5^3.0 Wl in
DMSO) were added and vF was measured from 0^60 s. 200 s after
the addition of inhibitor, secretagogue (6 Wl of 0.25 M 4AP, 3 Wl of
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10 mM veratridine, 15 Wl of 3 M KCl or 3.0 Wl of 25 mM monensin)
was added and the initial vF (0^60 s) was measured. The £uorescence
signal was calibrated by adding 5 nmol of L-glutamate to the cuvette
at the end of each experiment.
Glutamate release evoked by 4AP, veratridine or KCl was meas-
ured to assess the involvement of presynaptic Na channels as targets
for drug actions. 4AP, a K channel blocker, destabilizes membrane
potential and causes repetitive spontaneous Na channel-dependent
(tetrodotoxin-sensitive) depolarizations which mimic depolarization of
nerve terminals by action potentials and lead to activation of Ca2
channels and neurotransmitter release. Veratridine activates Na
channels directly and thereby depolarizes the plasma membrane lead-
ing to Ca2 channel activation and Na channel-dependent (tetrodo-
toxin-sensitive) neurotransmitter release. Elevated extracellular KCl
concentrations depolarize the plasma membrane by shifting the K
equilibrium potential above the threshold potential for activation of
Ca2 channels, leading to Ca2 entry and Na channel-independent
(tetrodotoxin-insensitive) neurotransmitter release, while Na chan-
nels are inactivated [12].
2.4. Measurement of [3H]BTX-B binding and 22Na+ in£ux
Equilibrium binding of 10 nM [3H]BTX-B to intact synaptosomes
in the presence of scorpion toxin (Leirus quinquestriatus) and veratri-
dine (60 WM)-stimulated Na in£ux into CHO CNaIIa cells was de-
termined as described [13].
2.5. Isolation of DRG neurons
Intermediate sized DRG neurons (15^40 Wm diameter) were isolated
from Sprague^Dawley rats aged 5^30 days by modi¢cation of de-
scribed methods [14,15]. Brie£y, animals were anesthetized with 80%
CO2/20% O2, decapitated and DRG were quickly removed and placed
in oxygenated, ice-cold normal or Ca2-free Hanks balanced salt so-
lution (5 mM KCl, 0.3 mM KH2PO4, 0.5 mM MgCl2, 0.4 mM
MgSO4, 137.9 mM NaCl, 0.3 mM Na2HPO4 and 5.6 mM glucose
þ 1.3 mM CaCl2) containing one or a combination (for control pur-
poses) of the following proteases (in w/v): trypsin (0.1^0.2%), colla-
genase (0.1%) or Pronase E (0.05^1%). The di¡erent combination of
proteases or the age of animals did not a¡ect the maximum Na
current and/or drug e¡ects. After enzyme incubation, ganglia were
placed in D-MEM/F-12 containing 20% (v/v) fetal bovine serum
and triturated with a Pasteur pipette. Dissociated cells were plated
on polylysine covered Petri dishes. Cells were used within a few hours
of dissociation and for up to 3 days of primary culture in 95% O2/5%
CO2 at 37‡C. The culture medium consisted of D-MEM/F-12 with
L-glutamine, 10% (v/v) fetal bovine serum, 100 U/ml penicillin and
100 Wg/ml streptomycin.
2.6. Electrophysiology
Na currents in DRG neurons were studied by whole-cell patch-
clamp recording using a standard patch-clamp ampli¢er (Axopatch
200, Axon Instruments, Foster City, CA, USA) that was controlled
by commercially available software (pCLAMP, Axon Instruments).
Patch-clamp pipettes were pulled from micropipette glass (Drum-
mond, Broomall, PA, USA) and ¢lled with intracellular solution (10
mM NaCl, 140 mM CsF, 5 mM HEPES, pH 7.2). The external so-
lution was Hanks balanced salt solution plus 20 mM tetraethylammo-
nium chloride, 5 mM HEPES and 5 WM LaCl3, pH 7.2. Under these
conditions, TTX-resistant channels, which are present in some DRG
neurons, were blocked [16], and only currents through TTX-sensitive
channels were recorded. This was veri¢ed by recordings in the pres-
ence of TTX (1 WM), which blocked all Na currents (data not
shown). Drugs were applied via a glass^PTFE perfusion system
with a superfusion pipette (£ow rate 0.5^0.8 ml/min) close to the
cell. Recordings were made at room temperature (22 þ 1‡C). Currents
were ¢ltered at 5 kHz, digitized and recorded to hard disk. Capacitive
transients and series resistance were measured and compensated using
the ampli¢er’s internal compensation circuitry; active series resistance
compensation was used to compensate 60^85% of the series resistance.
Cells with currents greater than 6 nA or less than 1 nA, or with
leakage greater than 5% of maximal Na conductance were rejected.
To estimate the application kinetics, we routinely examined currents
with a test pulse to +10 mV from a holding potential of 370 mV. The
voltage protocol used to measure current^voltage (I^V) relationships
consisted of a preconditioning step to 3100 mV and test pulses from a
holding potential of 370 mV to test potentials of 360 to +70 mV.
The voltage protocol used to measure steady-state inactivation con-
sisted of prepulses to varying potentials (500 ms to potentials between
3150 and 310 mV) and a test pulse to +10 mV.
2.7. Data analysis
Statistical di¡erences between control and experimental values were
determined by analysis of variance (ANOVA) with Fisher’s post hoc
test or Student’s t-test as appropriate. Concentration^e¡ect data were
analyzed for IC50 values by linear regression using data between 20
and 80% of the maximal response (Pharm/PCS Pharmacologic Calcu-
lation System, Version 4.2, Springer, New York, NY, USA). Values
are expressed as mean þ S.D. Electrophysiological analysis was per-
formed on-line with a second acquisition computer using pCLAMP6.
Curve ¢ts and statistical analysis were performed using commercially
available software: Origin and pCLAMP Module for Origin (Micro-
cal Software, Northampton, MA, USA).
2.8. Miscellaneous
Protein concentrations were determined by the Coomassie blue
method [17] using BSA as a standard.
3. Results
3.1. E¡ects of Ro 31-8220 on rat cortical synaptosomal Na+
channels
Ro 31-8220 inhibited glutamate release evoked by 1 mM
4AP or 20 WM veratridine, but not by 30 mM KCl or 50 WM
monensin (Fig. 1A). A similar pattern of inhibition was ob-
served for 1 WM TTX (data not shown), suggesting the in-
volvement of Na channels in the Ro 31-8220 e¡ect. This
possibility was supported by the observations that Ro 31-
8220 potently inhibited [3H]BTX binding to synaptosomes
(IC50 = 1.1 WM; Fig. 1B) by a competitive mechanism (data
not shown). Ro 31-8220 also inhibited veratridine-stimulated
Fig. 1. E¡ects of Ro 31-8220 on synaptosomal Na channels. A:
Ro 31-8220 inhibited Na channel-dependent glutamate release
evoked by 4-aminopyridine and veratridine, but not Na channel-in-
dependent glutamate release evoked by elevated KCl or monensin.
B: Ro 31-8220 inhibited speci¢c [3H]BTX-B binding to synaptoso-
mal Na channels. Summary data expressed as mean þ S.D. (n = 3).
*P6 0.05 versus control (no Ro 31-8220) by ANOVA with Fisher’s
post hoc test.
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22Na in£ux into CHO cells expressing rat CNaIIa Na chan-
nels (10.2 þ 0.79 (control) versus 7.26 þ 1.25 (3.3 WM Ro 31-
8220) nmol/min/mg protein; P6 0.05, n = 3). Bisindolylmalei-
mide I (GF 109203X; 5^20 WM) also signi¢cantly inhibited
glutamate release evoked by veratridine (24, 39 and 85% in-
hibition by 5, 10 and 20 WM, respectively), but not by elevated
KCl, while the non-selective isoquinolinesulfonamide protein
kinase inhibitor H7 (100 WM) did not signi¢cantly a¡ect either
(data not shown).
3.2. E¡ects of PKC inhibitors on DRG neuronal Na+ currents
Ro 31-8220 signi¢cantly inhibited peak Na currents in
isolated rat DRG neurons in a concentration-dependent man-
ner (Fig. 2, left). Signi¢cant e¡ects were observed within 20 s
of solution exchange, maximal e¡ects were observed within
2 min of application and no further changes in Na current
were observed for 20^40 min, depending on the drug. There-
fore, drug e¡ects were measured after 2 min of application,
when compounds had reached an apparent steady-state. There
was no signi¢cant e¡ect on the voltage-dependence of inacti-
vation (Fig. 2, right). In contrast, H7 had no signi¢cant e¡ect
on DRG Na currents (Fig. 3). Bisindolylmaleimide I (GF
109203X) and bisindolylmaleimide V (inactive against PKC),
which are structurally related to Ro 31-8220 but di¡er in their
activity as PKC inhibitors, both signi¢cantly inhibited peak
Na currents, but with slightly lower potencies (Fig. 3).
4. Discussion
Our results demonstrate that the bisindolylmaleimides Ro
31-8220 and GF 109203X, among the most commonly used
PKC inhibitors [1,2,18], inhibit voltage-dependent Na chan-
nels at concentrations commonly employed in experiments to
inhibit PKC. Inhibition by the ‘selective’ PKC inhibitor Ro
31-8220 of Na channel-dependent, but not of Na channel-
independent, glutamate release is consistent with the inhibi-
tion of presynaptic Na channels. Thus, tetrodotoxin-sensitive
glutamate release evoked by 4-aminopyridine or veratridine
was inhibited by 10 WM Ro 31-8220 (by 50^70%), while te-
trodotoxin-insensitive glutamate release evoked by elevated
KCl or the Na/H ionophore monensin was not inhibited.
The mechanism of inhibition of 4AP- and veratridine-evoked
glutamate release by Ro 31-8220 could involve: (1) blockade
of presynaptic Na channels required for terminal depolariza-
tion; (2) blockade of presynaptic Ca2 channel subtype(s)
coupled to glutamate release; (3) interference with synaptic
vesicle fusion/release mechanisms; (4) inhibition of reversed
Na/glutamate transport and/or (5) stimulation of glutamate
reuptake. The absence of Ro 31-8220 e¡ects on KCl- or mon-
ensin-evoked release suggests that inhibition of glutamate re-
lease involves primarily a blockade of Na channels, though
some contribution by the other mechanisms could also be
involved. This interpretation is supported by the observations
that Ro 31-8220, as well as the chemically related bisindolyl-
maleimides I and V [19], inhibited somatodendritic Na cur-
rents measured by whole-cell patch-clamp recording of iso-
lated DRG neurons. The e¡ects of bisindolylmaleimides I,
Fig. 2. E¡ects of Ro 31-8220 on whole-cell Na current in isolated DRG neurons. Left: Representative peak current^voltage relationships are
shown for currents in the presence and absence of Ro 31-8220, elicited by voltage steps from a conditioning potential of 3100 mV to test po-
tentials varying from 360 to +100 mV in two separate cells. Right: E¡ect of Ro 31-8220 on Na channel steady-state inactivation. Na cur-
rents were elicited by test pulses to 310 mV after 500 ms pre-pulses to potentials varying from 3150 to 310 mV. Representative peak currents
were normalized and plotted as a function of pre-pulse potential.
Fig. 3. E¡ects of various PKC inhibitors on whole-cell Na current
in isolated DRG neurons. Summary data are expressed as
mean þ S.D. (n = 3) and normalized to control Na current in the
absence of drug. Black: Ro 31-8220; open: H7; gray: GF 1092037;
hatched: bisindolylmaleimide V. All values, except those for H7,
were signi¢cantly di¡erent from control (P6 0.05 by ANOVA).
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IX (inhibitors of PKC) and V (inactive against PKC) suggest
that a common structural feature of the bisindolylmaleimides
distinct from that involved in PKC inhibition is involved in
Na channel inhibition.
Rat brain CNaIIa Na channels expressed in CHO cells are
themselves regulated by phosphorylation [20]. Several obser-
vations indicate that inhibition of Na channels by bisindo-
lylmaleimides is direct rather than a consequence of inhibition
of channel phosphorylation by PKC: (1) phosphorylation by
PKC inhibits channel activity [20] ; (2) bisindolylmaleimide V
(inactive), but not the structurally unrelated PKC inhibitor
H7, inhibited Na channels; (3) the onset of Na inhibition
by bisindolylmaleimides measured electrophysiologically was
rapid (within 20 s of application) and (4) Ro 31-8220 inhibited
[3H]BTX-B binding. The latter two ¢ndings also make an
e¡ect mediated by inhibition of a Na channel kinase other
than PKC unlikely.
Inhibition of Na channels must be added to the growing
list of additional e¡ects of these ‘speci¢c’ PKC inhibitors,
which now includes inhibition of other protein kinases [4,5],
ligand-gated ion channels [6,7] and G protein-coupled recep-
tors [8]. Ro 31-8220 and GF 109203X are potent inhibitors of
the conventional isoforms of PKC with IC50 values in the
nanomolar range [1,2]. Nevertheless, inhibition of PKC in
intact cellular systems requires much higher inhibitor concen-
trations (i.e. micromolar) to overcome the e¡ects of high in-
tracellular PKC concentrations, high ATP concentrations and
cell membrane permeability barriers. These higher inhibitor
concentrations are able to inhibit a number of other targets
in addition to PKC. This lack of speci¢city makes use of these
inhibitors insu⁄cient to implicate PKC in the regulation of a
physiological process in the absence of corroborative data.
Despite these limitations, our results suggest an approach
by which bisindolylmaleimide inhibitors can be used to probe
the role of PKC in the regulation of physiological processes in
excitable cells (which contain Na channels). Inhibition of a
process by a bisindolylmaleimide inhibitor (Ro 31-8220 or GF
109203X) alone is inconclusive. Inhibition of the process by
both a bisindolylmaleimide inhibitor and by H7, but not by
bisindolylmaleimide V, provides strong support that PKC is
involved since H7 does not signi¢cantly inhibit Na channels.
Conversely, inhibition of the process by both a bisindolylma-
leimide inhibitor and to a lesser extent by bisindolylmaleimide
V, but not by H7, suggests a role for Na channels rather
than PKC in the process.
Studies that employ bisindolylmaleimide PKC inhibitors as
speci¢c pharmacological probes for PKC involvement must be
reevaluated in light of these ¢ndings. For example, Co¡ey et
al. [21] interpreted the observation that 10 WM Ro 31-8220
inhibited 4AP-evoked, but not elevated KCl-evoked, gluta-
mate release from rat cortical synaptosomes as evidence that
PKC plays a major role in regulating the depolarization of the
terminal. Cousin et al. [22] interpreted the observation that 10
WM Ro 31-8220 inhibited electrical ¢eld-evoked, but not ele-
vated KCl-evoked, [3H]D-aspartate release from rat cerebellar
granule cells as evidence that PKC plays a major role in ¢eld-
evoked release. Our results suggest the alternative interpreta-
tion that these e¡ects are due to Na channel block by Ro 31-
8220.
In conclusion, Ro 31-8220 and GF 109203X, which are
often employed as speci¢c inhibitors of PKC, are also able
to directly block neuronal voltage-dependent Na channels.
Acknowledgements: Supported by National Institutes of Health grant
GM 58055, Bethesda, MD, USA (H.C.H.) and a fellowship from the
Norman and Rosita Winston Foundation in Biomedical Sciences,
New York, NY, USA (R.L.).
References
[1] Hemmings, H.C., Jr. (1997) in: Neuromethods (Hemmings, H.C.,
Jr., Ed.), Vol. 30, pp. 121^218. Humana, Totowa, NJ.
[2] Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Per-
ret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E. and
Loriolle, F. (1991) J. Biol. Chem. 266, 15771^15781.
[3] Hanks, S.K., Quinn, A.M. and Hunter, T. (1988) Science 241,
42^52.
[4] Hers, I., Tavare¤, J.M. and Denton, R.M. (1999) FEBS Lett. 460,
433^436.
[5] Alessi, D.R. (1997) FEBS Lett. 402, 121^123.
[6] Coultrap, S.J., Sun, H., Tenner, T.E. and Machu, T.K. (1999)
J. Pharmacol. Exp. Ther. 290, 76^82.
[7] Marley, P.D. and Thomson, K.A. (1996) Br. J. Pharmacol. 119,
416^422.
[8] Lazareno, S., Popham, A. and Birdsall, N.J.M. (1998) Eur. J.
Pharmacol. 360, 281^284.
[9] Dunkley, P.R., Jarrie, P.E., Heath, J.W., Kidd, G.J. and Rostas,
J.A.P. (1986) Brain Res. 372, 115^129.
[10] Ratnakumari, L. and Hemmings Jr., H.C. (1997) Anesthesiology
86, 428^439.
[11] Nicholls, D.G., Talvinder, S.S. and Sanchez-Prieto, J. (1987)
J. Neurochem. 49, 50^57.
[12] Nicholls, D.G. (1993) Eur. J. Biochem. 212, 613^631.
[13] Ratnakumari, L. and Hemmings Jr., H.C. (1996) Br. J. Pharma-
col. 119, 1498^1504.
[14] Kostyuk, P.G., Veselovsky, N.S. and Tsyndrenko, A.Y. (1981)
Neuroscience 6, 2423^2430.
[15] Scott, B.S. and Edwards, B.A. (1980) J. Neurobiol. 11, 291^301.
[16] Yoshida, S. (1994) Cell Mol. Neurobiol. 14, 227^244.
[17] Bradford, M.M. (1976) Anal. Biochem. 72, 248^254.
[18] Wilkinson, S.E., Parker, P.J. and Nixon, J.S. (1993) Biochem. J.
294, 335^337.
[19] Davis, P.D., Elliott, L.H., Harris, W., Hill, C.H., Hurst, S.A.,
Keech, E., Kumar, M.K., Lawton, G., Nixon, J.S. and Wilkin-
son, S.E. (1992) J. Med. Chem. 35, 994^1001.
[20] Li, M., West, J.W., Numann, R., Murphy, B.J., Scheuer, T. and
Catterall, W.A. (1993) Science 61, 1439^1442.
[21] Co¡ey, E.T., Sihra, T.S. and Nicholls, D.G. (1993) J. Biol.
Chem. 268, 21060^21065.
[22] Cousin, M.A., McLaughlin, M. and Nicholls, D.G. (1999) Eur. J.
Neurosci. 11, 101^109.
FEBS 23665 8-5-00
R. Lingameneni et al./FEBS Letters 473 (2000) 265^268268
